{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:40:17Z","timestamp":1759974017390,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.medmal.2009.12.002","type":"journal-article","created":{"date-parts":[[2010,1,22]],"date-time":"2010-01-22T06:41:23Z","timestamp":1264142483000},"page":"440-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anidulafungine\u00a0: une nouvelle option th\u00e9rapeutique dans les candidoses syst\u00e9miques"],"prefix":"10.1016","volume":"40","author":[{"given":"F.","family":"Lanternier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2009.12.002_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/380637","article-title":"Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991\u20132000","volume":"38","author":"Marchetti","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.12.002_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/520192","article-title":"Nosocomial bloodstream infections in United States hospitals: a three-year analysis","volume":"29","author":"Edmond","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.12.002_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10096-004-1103-y","article-title":"Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study","volume":"23","author":"Tortorano","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2009.12.002_bib4","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1128\/JCM.43.4.1829-1835.2005","article-title":"Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002\u00a0to 2003","volume":"43","author":"Almirante","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.medmal.2009.12.002_bib5","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1128\/AAC.00496-07","article-title":"In vitro susceptibility to posaconazole of 1,903\u00a0yeast isolates recovered in France from 2003\u00a0to 2006\u00a0and tested by the method of the European Committee on Antimicrobial Susceptibility Testing","volume":"51","author":"Lortholary","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.12.002_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1128\/JCM.01551-06","article-title":"Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338\u00a0clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods","volume":"45","author":"Pfaller","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.medmal.2009.12.002_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1086\/505204","article-title":"Anidulafungin: a novel echinocandin","volume":"43","author":"Vazquez","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.12.002_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/14787210.5.1.45","article-title":"Anidulafungin: a new echinocandin for candidal infections","volume":"5","author":"De la Torre","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.medmal.2009.12.002_bib9","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1128\/JCM.43.11.5425-5427.2005","article-title":"In vitro activities of anidulafungin against more than 2,500\u00a0clinical isolates of Candida spp., including 315\u00a0isolates resistant to fluconazole","volume":"43","author":"Pfaller","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.medmal.2009.12.002_bib10","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1128\/AAC.47.10.3149-3154.2003","article-title":"Antifungal susceptibility survey of 2,000\u00a0bloodstream Candida isolates in the United States","volume":"47","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.12.002_bib11","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1128\/AAC.41.11.2576","article-title":"In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species","volume":"41","author":"Karlowsky","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.12.002_bib12","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1517\/13543784.13.9.1183","article-title":"Anidulafungin: an echinocandin antifungal","volume":"13","author":"Pfaller","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.medmal.2009.12.002_bib13","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1128\/AAC.43.9.2148","article-title":"Antifungal activity of LY303366, a novel echinocandin\u00a0B, in experimental disseminated candidiasis in rabbits","volume":"43","author":"Petraitiene","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.12.002_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/AAC.45.2.471-479.2001","article-title":"Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis","volume":"45","author":"Petraitis","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.12.002_bib15","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/0091270004265644","article-title":"Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal","volume":"44","author":"Dowell","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.medmal.2009.12.002_bib16","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1517\/14656566.8.10.1479","article-title":"A comparative evaluation of properties and clinical efficacy of the echinocandins","volume":"8","author":"Kim","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.medmal.2009.12.002_bib17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0091270006297227","article-title":"Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment","volume":"47","author":"Dowell","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.medmal.2009.12.002_bib18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.clinthera.2005.06.010","article-title":"Anidulafungin: a new echinocandin with a novel profile","volume":"27","author":"Vazquez","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.medmal.2009.12.002_bib19","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1177\/0091270005281234","article-title":"Safety and pharmacokinetics of coadministered voriconazole and anidulafungin","volume":"45","author":"Dowell","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.medmal.2009.12.002_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0091270004270146","article-title":"Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine","volume":"45","author":"Dowell","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.medmal.2009.12.002_bib21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0091270006296764","article-title":"Lack of pharmacokinetic interaction between anidulafungin and tacrolimus","volume":"47","author":"Dowell","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.medmal.2009.12.002_bib22","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/AAC.48.6.2021-2024.2004","article-title":"Phase\u00a02, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia","volume":"48","author":"Krause","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2009.12.002_bib23","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2009.12.002_bib24","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","article-title":"A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of oesophageal candidiasis","volume":"39","author":"Krause","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.12.002_bib25","unstructured":"European Public Assessment Report (EPAR) Ecalta. http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/ecalta\/ecalta.htm."}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X0900393X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X0900393X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:08:08Z","timestamp":1759972088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X0900393X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0399077X0900393X"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2009.12.002","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anidulafungine\u00a0: une nouvelle option th\u00e9rapeutique dans les candidoses syst\u00e9miques","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2009.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}